Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloNK + rituximab
- Development stage
- Unknown
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AlloNK + rituximab is a **combination therapy** consisting of AlloNK (AB-101), a non-genetically modified, cord blood-derived, allogeneic natural killer (NK) cell therapy, and rituximab, an anti-CD20 monoclonal antibody. AlloNK is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) by providing NK cells which work synergistically with rituximab to promote deep and durable B-cell depletion. This combination is being evaluated for several autoimmune diseases, such as systemic lupus erythematosus (SLE) including lupus nephritis (LN), rheumatoid arthritis (RA), Sjögren’s disease (SjD), idiopathic inflammatory myopathies (IIMs), systemic sclerosis (SSc), pemphigus vulgaris (PV), vasculitis (GPA/MPA, AAV), and also in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)[1][3][6][7].
- Brand names
- AlloNKRituxanMabThera
- Other names
- AlloNK + rituximabAB-101 + rituximab
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on AlloNK + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloNK + rituximab.